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ABSTRACT
Background Control of asthma is the goal of asthma
management worldwide. The Global Initiative for Asthma
deﬁned control by a composite measure of clinical ﬁndings
and future risk but without using markers of airway
inﬂammation, the hallmark of asthma. We investigated
whether clinical asthma control reﬂects eosinophilic
inﬂammation in a broad population.
Methods Control of asthma was assessed over a period
of 4 weeks in 111 patients with asthma: 22 totally
controlled, 47 well controlled and 42 uncontrolled. Lung
function, quality of life, airway hyperresponsiveness to AMP,
sputum and blood eosinophils, exhaled nitric oxide (NO)
and bronchial biopsies were obtained.
Results The 69 subjects with controlled asthma (totally
and well controlled combined) had lower median blood
eosinophil numbers, slope of AMP hyperresponsiveness,
and alveolar NO levels than the 42 subjects with
uncontrolled asthma: 0.18 (range 0.01–0.54) versus 0.22
(0.06–1.16)×109/litre (p<0.05), 3.8 (−0.4–17 750) versus
39.7 (0.4–28 000) mg/ml (p<0.05) and 5.3 (1.5–14.9)
versus 6.7 (2.6–51.7) ppb (p<0.05) respectively. Biopsies
from subjects with controlled asthma contained fewer
eosinophilic granules and more intact epithelium than
uncontrolled subjects: 113 (6–1787) versus 219 (19–5313)
(p<0.05) and 11.8% (0–65.3) versus 5.6% (0–47.6)
(p<0.05) respectively. Controlled asthmatics had better
Asthma Quality of Life Questionnaire scores than
uncontrolled patients: 6.7 (5.0–7.0) versus 5.9 (3.7–7.0)
(p<0.001).
Conclusions The level of asthma control, based on a
composite measure of clinical ﬁndings, is associated with
inﬂammatory markers, particularly eosinophilic
inﬂammation, with little difference between totally
controlled and well controlled asthma.
INTRODUCTION
Aiming for total control of asthma by applying strict
rules for treatment was the focus of the Gaining
Optimal Asthma Control (GOAL) study in 2004.1 In
this landmark study, totally controlled and well con-
trolled asthma were composite measures based on
respiratory symptoms during the day and night, use of
rescue medication, peak expiratory ﬂow (PEF) rate,
exacerbations, emergency visits to the doctor or hos-
pital, and adverse side effects of treatment.1 Indeed,
many patients with uncontrolled asthma improved to
a well controlled or totally controlled level after step-
wise increase of ﬂuticasone or ﬂuticasone combined
with salmeterol. In 2006 the Global Initiative for
Asthma (GINA)2 emphasised the importance of
asthma control, and also deﬁned it on the basis of a
composite measure of clinical indices, with a later
modiﬁcation to include an assessment of the patient’s
future risk of adverse events. It was recognised that
the clinical features of asthma could be well controlled
in patients with mild, moderate or severe disease,
as indicated by the level of treatment required.3
Surprisingly, a marker of inﬂammation was not
included in the deﬁnition of asthma control, whereas
chronic airway inﬂammation is the hallmark of
asthma.
Airway inﬂammation does not correlate well with
the level of lung function or symptoms of asthma.4
The question arises as to whether well or totally con-
trolled asthma based on clinical criteria alone sufﬁ-
ciently reﬂects an adequate control of the underlying
airway inﬂammation. Furthermore, while a patient
may not perceive it as important to have minimal
airway inﬂammation, optimal quality of life may be
much more important.5 Therefore, a more thorough
insight is needed into the complex interplay between
clinical control of asthma, quality of life and the
underlying airway inﬂammation. Previous studies
have focused on the relationship between asthma
severity (deﬁned at the time by symptoms and lung
function) and eosinophilic inﬂammation.5–7 In this
observational study we investigated multiple measures
of eosinophilic airway inﬂammation and quality of
life in subjects with totally controlled, well controlled




Smoking and non-smoking patients with asthma,
aged 19–71 years, either using or not using inhaled
Key messages
▸ Control of asthma, based on a composite
measure of clinical ﬁndings, is associated with
direct and indirect markers of inﬂammation,
particularly eosinophils.
▸ From the patients’ perspective it is important to
note that this composite measure is related to
their quality of life.
▸ The relationship between clinical and
inﬂammatory measures is not strong, indicating
that inﬂammatory markers provide additional
information about a patient’s asthma status.
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corticosteroids (ICS), were recruited from research cohorts in
Groningen, the Netherlands. All subjects had a past doctor’s
diagnosis of asthma and documented bronchial hyperresponsive-
ness to histamine (provocative concentration of histamine
causing a 10% fall in forced expiratory volume in 1 s (FEV1)
from baseline (PC10 histamine) ≤16 mg/ml, using 30 s tidal
breathing). Moreover, patients were included if they had a pro-
vocative concentration of AMP causing a 20% fall in FEV1 from
baseline (PC20 AMP) ≤320 mg/ml. If PC20 AMP was higher, an
additional histamine provocation challenge was performed
within 2 weeks and subjects had to demonstrate a PC10 hista-
mine ≤16 mg/ml. The main exclusion criteria were: FEV1 <1.2
litre, chronic obstructive pulmonary disease, bronchiectasis,
upper respiratory tract infection (eg, colds) and/or use of anti-
biotics or oral corticosteroids within 2 months prior to inclusion
in the study. The local medical ethics committee approved the
study protocol and all subjects gave their written informed
consent.
Study design
This prospective cross-sectional study involved subjects paying
four visits to the clinic. At visit 1, written informed consent was
obtained and patients were enrolled in the study if they fulﬁlled
the inclusion criteria. Patients were instructed how to keep a
diary and how to measure PEF at home for the next 4 weeks. At
visit 2 (4 weeks later), clinical control of asthma was assessed
from the diary according to the GOAL criteria (table E1 in
online supplement) and quality of life was determined using the
Asthma Quality of Life Questionnaire (AQLQ).8 Blood was
drawn for measurement of eosinophils and atopy. Then revers-
ibility of FEV1 was carried out with 800 mg of inhaled albuterol
(Ventolin) followed by sputum induction. Within 2 weeks, at
visit 3, hyperresponsiveness to AMP was assessed. One to two
weeks later this was followed by exhaled nitrogen monoxide
(NO) measurements and a bronchoscopy (visit 4).
Atopy
The Phadiatop screening test was used to determine atopic
status; it was performed on the ImmunoCap system, according
to the manufacturer’s instructions (Phadia AB, Uppsala,
Sweden). The results are presented as quotients (ﬂuorescence of
the serum of interest divided by the ﬂuorescence of a control
serum). A positive Phadiatop was deﬁned as patient serum/
control serum >1.
Asthma quality of life
The Dutch version of the AQLQ was used for this study.8 The
AQLQ is scored on a seven-point scale, with 32 questions on
four domains: symptoms, responses to environmental stimuli
and the need to avoid them, limitation of activities and emo-
tional dysfunction.
Lung function
FEV1 was measured with a calibrated water-sealed spirometer
according to standardised guidelines.9 Reversibility of FEV1%
predicted was measured with administration of 800 μg of albu-
terol. Provocation tests were performed using a method adapted
from Cockcroft et al.10 After initial nebulised normal saline, sub-
jects inhaled doubling concentrations of AMP (0.04–320 mg/ml)
by 2 min tidal breathing and at 5 min intervals. The slope of the
AMP curve was calculated as the ratio between the change in
FEV1 (difference between the value at baseline and at ﬁnal dose
of AMP) and the ﬁnal dose of AMP. Bronchial hyperresponsive-
ness to histamine was tested as reported previously,11 using the
30 s tidal breathing method and doubling concentrations ranging
from 0.13 to 32 mg/ml.
Sputum induction and sputum processing
Sputum was induced by inhalation of hypertonic saline aerosols
as previously described.12 Hypertonic saline (5%) was nebulised
over three consecutive periods of 5 min. Whole sputum samples
were processed according to a method modiﬁed from that of
Fahy et al.12 13 May Grünwald Giemsa staining was used
to obtain cell differentials from a total of 600 viable, non-
squamous cells. The sputum was not evaluated if the percentage
of squamous cells was >80% or if the total number of non-
squamous cells was <600.
Alveolar and bronchial nitric oxide
Exhaled NO (eNO) measurement was performed at multiple
ﬂow rates (30, 50, 100 and 200 ml/s) on a NIOX (Aerocrine,
Stockholm, Sweden). The mean eNO value (ppb) of three tech-
nically acceptable attempts per ﬂow rate was used for analysis.
The alveolar NO fraction (ppb) and the bronchial NO ﬂux (nl/s)
were calculated with a modiﬁcation of the two-compartment
model of NO exchange by Tsoukias and George.14 15
Collection, processing, immunohistochemical staining and
quantiﬁcation of bronchial biopsies
After local anaesthesia, bronchial biopsies were obtained using a
ﬂexible bronchoscope (Olympus BF P20 or BF XT20) from seg-
mental divisions of the main bronchi. The biopsies were ﬁxed in
4% formalin, processed and embedded in parafﬁn. Bronchial
biopsies were cut into 3 mm thick sections and stained with spe-
ciﬁc antibodies against a large panel of inﬂammatory markers.
The inﬂammatory cells were quantiﬁed using computer-assisted
image analysis (see Methods section in the online supplement
for more details).
Statistics
All analyses were performed using SPSS V.14.0.1. The differ-
ences in the continuous variables between groups were tested
with the Mann–Whitney U test for non-normally distributed
data and with the independent sample t test for normally dis-
tributed data. PC20 AMP, slope of AMP, blood, sputum and
bronchial eosinophils, and eNO were transformed logarithmic-
ally to normalise their distribution. We compared the groups’
dichotomous variables using the χ2 test and performed multiple
logistic regression analysis to investigate which variables were
signiﬁcant determinants for asthma control.
RESULTS
Patient characteristics
One hundred and eleven patients with asthma with a median
age of 50 years (range 19–71) were included (table 1). The
reasons for not having totally controlled or well controlled
asthma are given in the online supplement (table E1).
Twenty-two subjects (20%) were totally controlled, 47 (42%)
well controlled and 42 (38%) uncontrolled.
Markers of inﬂammation
The 69 subjects with controlled asthma (totally and well con-
trolled combined) had lower median blood eosinophil numbers
than subjects with uncontrolled asthma: 0.18 (range 0.01–0.54)
versus 0.22 (0.06–1.16)×109/litre (p<0.05) (ﬁgure 1). The
slope of PC20 AMP was lower in patients with controlled asthma
than in those with uncontrolled asthma: 3.8 (−0.4–17 750)
versus 39.7 (0.4–28 000) mg/ml (p<0.05). Alveolar NO levels
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were lower in subjects with controlled asthma than with
uncontrolled asthma: 5.3 (1.5–14.9) versus 6.7 (2.6–51.7) ppb
(p<0.05) (Figure 1).
Sputum was evaluable in 72% of the subjects, which may
have caused some bias to the results. The total number and pro-
portion of inﬂammatory cell types did not differ signiﬁcantly
between controlled and uncontrolled subjects (table E2 in
online supplement). Post hoc analysis in subgroups of patients
with asthma divided according to current smoking status and
current corticosteroid use did not affect these results. However,
sputum eosinophils were less frequently outside the normal
range of >1.9%16 in subjects with controlled asthma versus
those with uncontrolled asthma: 9 (19%) versus 13 (39%)
respectively (p<0.05). Using a cut-off point >3% values were 7
(16%) versus 12 (36%) respectively (p<0.05). Subjects with
controlled asthma had a lower level of eosinophil activation
than uncontrolled subjects, as determined by eosinophil perox-
idase (EPX) immunopositivity in bronchial biopsies (table 2,
ﬁgure 2). Controlled asthma was accompanied by an increase in
intact epithelium compared with uncontrolled asthma (table 2,
ﬁgure 2). All other inﬂammatory and remodelling variables we
investigated were comparable in subjects with controlled and
uncontrolled asthma (tables 2 and E3 in online supplement).
No differences were found in markers of inﬂammation
between well controlled and totally controlled asthma.
However, the slope of PC20 AMP tended to be higher in sub-
jects with totally controlled asthma than in those with well con-
trolled asthma (p=0.08) (ﬁgure 1).
Multiple logistic regression analysis on asthma control
Multivariate logistic regression analysis was used to reveal which
variables were independently associated with the level of clinical
control. Due to multicolinearity all the variables related to eosino-
philic inﬂammation could not be entered simultaneously into
the model. We therefore created a model including sex, age,
Phadiatop ratio, ICS use and FEV1/vital capacity, in which we
entered alveolar NO, blood eosinophils, AMP slope, EPX-positive
pixels and the percentage intact epithelium separately. This
showed that higher Phadiatop ratio and ICS use were signiﬁcant
determinants of worse asthma control in most of the models. It is
noteworthy that a higher AMP slope (OR 0.39; 95% CI 0.24 to
0.63) and higher EPX-positive pixel numbers (OR 0.32; 95% CI
0.13 to 0.79) were signiﬁcant determinants for worse asthma
control (see Results section in online supplement).
Comparison with asthma quality of life
Subjects with controlled asthma demonstrated higher median
scores in the total AQLQ than uncontrolled subjects: 6.7 (range
5.0–7.0) versus 5.9 (3.7–7.0) (p<0.001) (ﬁgure 3). They also
had signiﬁcantly higher scores in all domains of the AQLQ:
symptoms 6.7 (4.9–7.0) versus 5.5 (3.7–7.0), activity 6.8
(4.5–7.0) versus 6.3 (3.9–7.0), emotion 7.0 (5.0–7.0) versus 6.6
(3.8–7.0) and environment 6.5 (3.8–7.0) versus 5.5 (3.0–7.0).
AQLQ scores did not differ signiﬁcantly between subjects with
totally controlled and well controlled asthma.
DISCUSSION
The focus of the GINA2 shifted in 2006 from asthma severity
before treatment to asthma control during treatment, with
assessment based on a composite measure of clinical ﬁndings.
There is now also considerable interest in controlling not only
the clinical manifestations of asthma, but also the inﬂammatory
and pathophysiological features of the disease.16 Although pre-
vious studies have described airway inﬂammation in patients
classiﬁed by asthma severity, based on past severity classiﬁcation
systems,5–7 our study is the ﬁrst to investigate whether the level
of asthma control according to GOAL is associated with direct
and indirect markers of airway inﬂammation. In a large group
of patients with asthma with a wide spectrum of disease severity,
patients with totally controlled and well controlled asthma
demonstrated less hyperresponsiveness to AMP, lower NO levels
in exhaled air, lower eosinophil numbers in peripheral blood,
lower activated eosinophil numbers and more epithelial intact-
ness in airway wall biopsies, and higher quality of life scores
than subjects with uncontrolled asthma.
Our data suggest that good clinical control of asthma is asso-
ciated with a lower degree of eosinophilic airway inﬂammation
as assessed by indirect markers like PC20 AMP, eNO and periph-
eral blood eosinophils. Even more importantly, we found that
good control of asthma was associated with less airway inﬂam-
mation as seen by the classical biopsy ﬁndings of mucosal inﬁl-
tration of activated eosinophils and better epithelial integrity.17
Thus, the concept of a composite measure for clinical asthma
control, combining different variables like night-time and
daytime symptoms, PEF, and use of rescue medication, appears










Sex (men/women) 10/12 21/26 22/20
Age (years) 48 (19–64) 52 (22–71) 48 (22–68)
Atopy (Phadiatop ratio) 4.93 (0.13–96.5) 5.56 (0.06–106) 27.3 (0.15–128)*‡
Pack years in all
subjects
0.9 (0–31) 2.0 (0–64) 0.2 (0–45)
Ex-smokers, n (%) 13 (59) 27 (57) 25 (60)
Current smokers, n (%) 7 (32) 12 (26) 10 (24)
Cigarettes/day in
current smokers
12.0 (3–20) 14.7 (3–20) 12.9 (3–15)
Ex-smokers, n (%) 13 (59) 27 (57) 25 (60)
Pack years in all
subjects
0.9 (0–31) 2.0 (0–64) 0.2 (0–45)
Patients using ICS,
n (%)
5 (23) 26 (55) 30 (71)**
Dose (mg/day) in all
subjects¶








3 (14) 15 (32) 16 (38)
Pre-bronchodilator
FEV1 (% predicted)
101 (71–114)§ 90 (34–129) 87 (42–128)‡*
Pre-bronchodilator
FEV1/FVC (%)
80 (58–97)§ 74 (39–88) 73 (40–97)‡
Reversibility FEV1 (%) 8.7 (0.7–23.9) 9.0 (1.5–23.3) 10.7
(–2.2 to 38.4)
PC20 AMP (mg/ml) 640 (8.1–640) 100 (0.1–640) 7.7
(0–640)***†‡‡
Values are medians (ranges), unless stated otherwise.
*p<0.05 or **p<0.01 or ***p<0.001 versus controlled, †p<0.001 versus well
controlled, ‡p<0.05 or ‡‡p<0.001 versus totally controlled, §p<0.05 versus well
controlled. Additional results are provided in Table E1 in the online supplement.
¶Dose equivalent of beclomethasone.
FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; ICS, inhaled
corticosteroids; LABA, long-acting β2 agonist, PC20 AMP, provocative concentration of
AMP causing a 20% fall in FEV1; reversibility FEV1 (%), change in FEV1 expressed as
increase in percentage predicted after 800 μg of albuterol.
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to have an underlying pathobiological substrate. However, the
associations between clinical control and eosinophilic inﬂamma-
tion were not strong, and no signiﬁcant differences were seen in
inﬂammation markers between totally controlled and well con-
trolled subjects. The lack of correlation between clinical control
and eosinophilic inﬂammation is consistent with emerging evi-
dence for heterogeneity in inﬂammatory phenotypes, particu-
larly in patients with non-corticosteroid responsive symptoms.18
We further demonstrate that different aspects of inﬂammation
(NO, eosinophils, epithelial cells, PC20 AMP) stemming from dif-
ferent parts of the lung (exhaled air, blood, bronchial biopsies)
are associated with good clinical control of asthma. This is not
particularly surprising since all these inﬂammatory factors inter-
act and contribute to the overall, general inﬂammation that is
present in asthma. However, the heterogeneity of asthma with
different inﬂammatory subtypes is increasingly acknowl-
edged.18 19 Our study also lends support to this concept, since
less severe AMP hyperresponsiveness, lower eosinophil numbers
and better epithelial integrity were all independently contributing
to better asthma control. Regardless of the exact relationship, our
results suggest that patients with better asthma control have less
eosinophilic inﬂammation, although the relationship appeared
weaker for sputum eosinophils than for biopsy or blood markers.
We had three unexpected ﬁndings in this study. First, the
number of pack years smoking or the current smoking status did
not contribute signiﬁcantly to the level of asthma control,
Figure 1 Biological parameters assessed in subjects with asthma. Peripheral blood eosinophils, sputum eosinophils (%), slope of AMP and
alveolar nitric oxide concentrations in patients with totally controlled, well controlled and uncontrolled asthma. Each dot represents one subject.
Horizontal bars represent median values. No signiﬁcant differences were found between totally controlled and well controlled asthma. NO, nitric
monoxide.











Eosinophils 2 (0–26) 1 (0–21) 2 (0–32)
Mast cells 12 (3–24) 8 (0–26) 9 (0–17)
Macrophages 15 (0–30) 12 (0–47) 11 (0–57)
Neutrophils 9 (0–46) 5 (0–34) 6 (0–20)
T lymphocytes (CD3+) 68 (23–294) 55 (13–177) 66 (4–219)
T lymphocytes (CD4+) 24 (4–70) 16 (0–67) 17 (0–71)
T lymphocytes (CD8+) 25 (4–139) 17 (0–136) 23 (1–205)
Inflammatory cell activation
EPX immunopositivity 157 (16–1268) 101 (6–1787) 219 (19–5312)*, **
Mast cell
degranulation (%)
80 (22–100) 69 (25–100) 75 (0–100)
Remodelling
BM thickness (mm) 6.3 (4.3–9) 5.2 (3.6–8.7) 5.9 (2.8–12.6)
Intact epithelium (%) 13 (0–32.8) 10.5 (0–65.3) 5.6 (0–47.6)*
Inflammatory cells are expressed as the number per 0.1 mm2. Values are medians
(ranges).
*p<0.05 versus controlled, **p<0.01 versus well controlled.
BM, basement membrane; EPX, eosinophil peroxidase.
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despite the fact that smoking has been associated with poorer
asthma control in other studies.20–22 One explanation could be
that the number of pack years smoking was low, just as the pro-
portion of current smokers. Another explanation might be a
‘healthy smoker’ effect, that is, those with relatively healthy
airways are able to tolerate smoke inhalation, to persist in their
smoking habit while still showing good control of their asthma.
Second, ICS use contributed to the variation in asthma
control, but in an opposite direction to that intuitively expected,
that is, patients with uncontrolled asthma used ICS more fre-
quently and with higher doses than patients with controlled
asthma. This is likely to represent indication bias, in that
patients with worse asthma control are more likely to be pre-
scribed ICS. In addition, an ‘unhealthy ICS’ effect may have
also been present in our study since it is known that some
patients with asthma do not respond well to corticosteroids.23 24
This was also found in the GOAL study, in which 20–30% of
the participants were still classiﬁed as having uncontrolled
asthma at the end of the study despite long-term administration
of increasing doses of ICS.
Third, the level of asthma control by GOAL criteria did not
signiﬁcantly associate with lower sputum eosinophil levels,
although signiﬁcantly more patients with uncontrolled asthma
had sputum eosinophils outside the normal range.16 Three pre-
vious studies, using a range of criteria for asthma control, have
shown different results. Romagnoli et al25 (n=35) found
median sputum eosinophil levels of 0% and 2.5% (p=0.01) in
patients classiﬁed as having controlled and poorly controlled
asthma, based on symptom frequency, night awakening, bron-
chodilator use and PEF variability. Quaedvlieg et al26 (n=134)
reported median sputum eosinophil levels of 0.4%, 1.4% and
5.6% (p=0.001 well controlled vs uncontrolled) for patients
with asthma classiﬁed as well controlled, borderline and
uncontrolled respectively by the six-item Asthma Control
Questionnaire.27 In contrast, Shiota et al28 (n=96) found no sig-
niﬁcant difference in sputum eosinophil levels for patients classi-
ﬁed as having total, partial and uncontrolled asthma by the
Asthma Control Test29 (2.1%, 3.8% and 4.9% respectively,
p=0.4). The differing eosinophil levels seen in these studies
emphasise the potential variation due to patient selection.
Unlike earlier studies, the present study also included eosino-
philic markers in peripheral blood and airway wall biopsies, and
these were found to better reﬂect a strict deﬁnition of asthma
control. It is an intriguing ﬁnding that control of asthma signiﬁ-
cantly associates with lower peripheral blood eosinophils and
lower activated eosinophil numbers in the bronchial wall, yet
only weakly with sputum eosinophils. Nevertheless, across all
three compartments, the ﬁndings demonstrate that assessment
of airway inﬂammation provides additional information about
asthma status than is obtained from clinical control measures.
The present study also conﬁrms that health-related quality of
life in patients with controlled asthma is signiﬁcantly better than
in uncontrolled asthma. As the difference between the two
groups was higher than the minimal, clinically important differ-
ence of 0.5 point, this emphasises the overall impact of asthma
control on health status.30 In addition, as in the GOAL study
itself,31 little difference was seen in absolute AQLQ scores
between subjects with well controlled and totally controlled
asthma, suggesting that further improvement in clinical asthma
control may not be reﬂected in a clinically important difference
in an individual’s quality of life.
The participants in this study are not fully comparable to
those in the larger GOAL study,1 32 which included only sub-
jects with uncontrolled asthma with a smoking history of <10
pack years, whereas we also included subjects with totally con-
trolled and well controlled asthma with no limit on smoking
Figure 2 Biopsy parameters assessed
in subjects with asthma. Eosinophil
peroxidase (EPX) immunopositivity (left
panel) and the percentage of intact
epithelium (right panel) in bronchial
biopsies of patients with totally
controlled, well controlled and
uncontrolled asthma. Each dot
represents one subject. Horizontal bars
represent median values. No
signiﬁcant differences were found
between totally controlled and well
controlled asthma.
Figure 3 Asthma quality of life as assessed with the Asthma Quality
of Life Questionnaire (AQLQ). The AQLQ ( Juniper et al8) was given to
subjects with totally controlled, well controlled and uncontrolled
asthma. It is divided into four domains: symptoms, activities, emotions,
environmental. Each dot represents one subject. Horizontal bars
represent median values. No signiﬁcant differences were found
between totally controlled and well controlled asthma.
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history. The GOAL study also included younger subjects (includ-
ing children) and had a lower prevalence of ex-smokers, had
lower lung function and higher bronchodilator reversibility.
When comparing the reasons why patients failed to achieve
total asthma control at baseline in the GOAL study32 and in our
study (Table E1) there are a few striking differences. The percen-
tages of patients failing to achieve total control due to the
GOAL criteria were 63% due to awakening in GOAL versus
19% in our study, daytime symptoms (95% vs 34%), rescue
medication (92% vs 26%), and PEF ≥80% predicted (72% vs
50%). Thus, the prevalence of daytime symptoms and rescue
medication in the GOAL study were considerably higher than in
our study. It is possible that the patients in the GOAL study had
more severe disease because they also had a lower baseline lung
function and more symptoms than our patients. Larger, explora-
tive studies, also including patients with more severe asthma,
will be needed to determine why some patients do not achieve
total control of their asthma and this may have important conse-
quences for the therapies prescribed.
In conclusion, our study demonstrates that clinical control of
asthma is associated with direct and indirect markers of airway
inﬂammation, but that airway inﬂammation provides different
information about asthma status from that provided by clinical
measures of control. Moreover, better asthma control associates
with a higher quality of life for the patients. Although aiming
for good clinical control of asthma, as recommended by the
GINA guidelines, is important for suppressing the underlying
airway inﬂammation and from a patient’s perspective, the
present ﬁndings do not support a routine increase in ICS treat-
ment for patients with well controlled asthma. Longitudinal
intervention studies are needed to assess if the control of asthma
concept may recognise patients with asthma who are at higher
future risk of exacerbations, accelerated decline in lung function
and side effects of treatment.
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